RNA tech inaugurates the new Kondratiev biotech cycleModerna up $75 in a single day damn. $90 since I bought.
Didn't buy at 346 when I posted about it but at the bottom of the pullback a bit below 400 on friday.
More and more people are accepting the vaccine, and new shots are coming.
And regular retail "dumb money", the one that creates bubble, has not paid attention to PFE & MRNA yet (somehow). These companies are more famous now than Coca-Cola or Bitcoin. The bubble has not even started yet. It is going to go GME.
I've been saying that vaccine hesitancy was U shape with the morons on the left of the IQ curve not trusting it for silly reason, and the gifted on the right of the IQ bell not trusting it for valid reason & being misunderstood. I was dead right!
I have also been saying that the propaganda was so stupid only morons would fall for it. Right again 🙃.
Now scientifically proven!
I'm not saying the vaccine is dangerous, just that the smartest people are the more skepticals, the ones that think for themselves and that don't just mindlessly follow what some celebrity says. There are plenty of reasons why they might be skepticals not just a "lizard psyops" (that's what the authorities tell to high school dropouts to get them to take the shot AND IT WORKS THEY FALL FOR THAT).
And my guess is, and I am very certainly right again, that the PHDs hesistant are mostly the more healthy ones, with the old & fat having a better risk to reward taking it (even if we do not know for sure what the risks actually are, there is no stop loss here).
So the most hesistant group is the PHDs, followed by (at the time) the "rednecks" (high school degree or less), and of course who is the least hesitant group? Bachelor & Master degrees. The dead average normies that think they are smart "I stoodid! I am edookataid!", the typical clueless idiot parrots that think they are smart for mindlessly repeating what they are told. Universities suck, no idea why the US doesn't follow the french system, China did. In the US it's even pay to win. Kids want the gov to spend more for their university so they can have fun.
Science has proven I was right about the propaganda only working with morons:
Vaccine hesitancy among the high school and less has gone, between January and May, from 35% to 20%. Meanwhile the PHDs hesitancy actually WENT UP! Lmao pesky nerds, it went from ~23% to 25% in May.
www.medrxiv.org
Fortunately for my investment the vast majority is convinced and will keep purchasing new vaccines and "booster shots" some hypocondriacs are even breaking the law to get several booster shots! Take as many as you want, as long as you (via the government) pay for them :)
And fortunately for my investment, the ignorant high school dropouts are literally too stupid to read let alone understand the FUD written by these pesky hesitant PHDs. But when a celibrity wearing a clown nose burps and farts and tells them the vaccine will make them normal they listen, when the media says that people that don't get the vaccine are silly flat earthers they fall for it, when the media tells them they should vaccinate their 3 year old because of some magical reason they listen, when they say the vaccine is efficient BUT not efficient if other people don't take it BUT it's efficient after all because you won't make a "serious" case BUT other people still have to take it because it could mutate into a more serious version so you have to pressure other people to take it they listen and they can't figure out they're preparing public opinion for more vaccines in the near future.
Pretty amazing that the constant hammering of propaganda, of every single trick in the books has ZERO effect on PHDS, no it even has a slight negative effect (maybe a few can be tricked by reverse psychology or something? Just annoy them enough till they hate you so much they do the opposite of what you claim you want), and the high school dropouts massively fall for childish first degree tricks that are so obvious they sometimes make me blush.
It's actually useless to try and warn people of the risk.
1- High IQs will only change their minds if they find rational evidence, and if there is evidence about something they'll know about it.
Plus they are arrogant c***s that think they're smarter than everyone else (because they are) and don't listen to anything anyone "probably inferior" says and are super stubborn. Easy to be confident when you have something to back it up with.
2- The mindless spineless sheep in the middle will mindlessly follow anything anyone screaming loud enough says, they wouldn't want to lose their average normie repetitive desk job. Their greatest fear is looking stupid because they know they aren't smart enough to understand all the intricacies and put their balls on the table (assert themselves) and say they know best than "the scientists" (wheareas the scientists can obviously), while they also know they are smarter than the low IQs they despise and fear being mistaken with. There is probably a lot of Dunning-Kruger effect going on in here too, with this group being smart enough to understand 2-3 things, but not smart enough to understand the whole picture and know that they don't know what they don't know.
3- The "in difficulty" group, the low IQs, well they have a natural distrust of science not sure why, I don't know because I didn't study it because I don't care about this group, I don't care because they have no money and therefore no money to lose to me and even if they sometimes have some even Bitcoin is too solid an investment for them they rather lose it in a regular (obvious) "2% a day" ponzi. I don't know. What I know is they fall for childish manipulation tactics, their whole life they've let someone else do the thinking for them, and they are the fuel to this rocket ship. And to be fair I don't despise them like I despise 2, but if they grow a third arm and drop dead big deal, not like we don't have enough deadweights on welfare. We got an ample supply of those, not to worry. What we are missing are more doctors, more inventors, more independant thinkers.
We have to fight against the minsinformation! These scary FUD tactics are causing potential clients to hesitate 😠.
It's not a "new experiment method" my own father was working on it (against cancer) when I was a baby. It's older than me.
If people would just sponteanously combust we would know it.
The hesitancy is more subtle than that, nothing regular folks should worry their little heads about 🙂
One of the reason why it's good to have a few individuals not take it is so we have a group to compare to.
Rather than whine about conflicts of interests, come and profit from it, get your piece of the pie 🤑
Biotech
Can SAVA get back to $100 in the short term? $SAVA (Cassava Sciences) saw an insane rally in 2021 from $7 to $145 on the hopes that its groundbreaking Alzheimer's treatment will yield promising results never before seen in the history of the disease. Currently there are no Alzheimer's modifying therapies on the market and if the data surrounding Cassava's main drug, simufilam, is accurate then it could be the first of its kind.
SAVA saw a sell-the-news event when it announced its promising results, suffering a 23% drop on July 29. Soon thereafter a Stat News article was released criticizing Cassava's results, citing a group of independent researchers. The stock dropped a total of 55% from highs.
Is this a buying opportunity? Obviously we are largely delving in uncharted territory and financial analysts/traders won't be able to infer whether the science is reliable or not. However, traders know how market cycles largely work. There is often a second wave of optimism after negative news coverage (whether a short report or a hit piece), driven by those who are willing to speculate.
SAVA is showing a bullish harami on the 1D and it has dropped to the Fibonacci golden pocket level, also at the 100 MA where it has routinely found support. This could be a buying opportunity for those who are in the market for a bit of risk. As long as #SAVA is above the 100 MA, I'm willing to hold it in the mid term and will ride the next wave of positive financial/medical news.
Entry: $79
SL: soft SL with manual monitoring if it breaches the 100 MA
TP: $88, $94, $100
Writing The SCPS?SCPS seeing another spike in trading volume late in the week (week of 8/1). After plotting out the fib retracement using "normal levels" and not ones from the crazy parabolic spike previously, you can see this 618 area has been a key support/resistance level. With the latest spark taking SCPS stock higher afterhours on 8/4, it so far managed to break back above the 618 area for the first time in weeks. No news, no filings, just social momo. But thanks to it being part of that "low float" crowd, it could be in the mix of possible "short squeeze stocks" that've grown in popularity. Looking at the deets...back in May there were a few fundamental developments to track:
" the company announced that it received FDA approval for an Investigational New Drug Application for its lead drug candidate, CpG-STAT3siRNA. Now, a Phase 1 trial for B-cell non-Hodgkin lymphoma will begin at the City of Hope. This is a well-known research and treatment center for cancer, diabetes, and other diseases.
More To Watch With SCPS Stock
As a newer company, Scopus has only been public since December of 2020. The company initially raised just under $3 million from its IPO debut. While this wasn’t technically a penny stock initially, shares hovered around $5 earlier this month. That was, until the news on May 24th. Since the announcement, SCPS stock has surged past the $17 mark. Furthermore, even though it’s a newer company, analysts have also begun following the company closely.
Benchmark Research started Scopus with a Speculative Buy rating as well as a price target of $20. Analyst Aydin Huseynov believes that the company’s STAT3 inhibitor gene therapy, CO-sTiRNA, has “a reasonable chance to show clinically relevant results” in recurrent and hard-to-treat aggressive Non-Hodgkin Lymphoma indications. Huseynov gave this outlook several months before today’s news and expected the IND submission during the second half of the year. "
Quote Source & Read More: 3 Biotech Penny Stocks To Watch That Analysts Are Bullish On Today
SAVA Stuck At 382It's interesting to see what happens after plotting out fib lines sometimes. SAVA , for instance...using the earlier lows and the recent high as anchors we can see that the 382 fib line has been a very clear area of both support and resistance almost to the exact mark. Sure 236 played this role before the Alzheimer's data but now SAVA has reset back to some familiar territory and, so far, is mimicking its trend before the big breakout, which is 382 fib resistance being an issue. Multiple times in the last few days, this area was tested and SAVA was rejected (including 8/3). BUT with the market seemingly building optimism, it could once again be an important area on the chart to be aware of.
"The biotech industry is well known for volatility. When you’re talking about developing life-changing treatments, there’s a lot to account for. The phase trial process brings the potential for big progress but can also put the brakes on otherwise strong rallies in the market. We recently saw this with companies like Cassava Sciences (NASDAQ: SAVA) and Annovis Bio (NYSE: ANVS ), which were also former penny stocks. Both companies developing Alzheimer’s treatments revealed data that didn’t impress the market at all. In response, shares of both stocks plummeted."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
BMY Flirting With Historic TerritoryWhen I say "historic" for BMY I'm not talking ATH but the stock's encroaching on an area that has been tested 3 times being rejected each time. This is the 236 fib area using 2016's high as the top anchor. It's been 5 years since BMY traded well above this area. But with the way attention is being placed on immunotherapy stocks, it could be something to keep in mind for BMY longs.
" Both Bristol-Myers and Novartis recently gave updates on new FDA updates. Novartis’ NIS793 gained FDA Orphan Drug Designation, while Bristol-Myers’ recent earnings update revealed strong sales figures from its lead cancer drug, Opdivo...B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment. While things are still in the very early stages for B7 molecules, as a whole, early research is also finding new potential for targeted cancer treatments. For instance, Merck’s (NYSE: MRK ) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment ."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
MRK Testing the upper limits But Can It Make New Highs?MRK is back in this 382-236 fib range with both lining up pretty tightly with the current levels on the chart. 382 is a bit looser and more of a pivot area, for now, that's been a magnet for the stock over the last few weeks. Meanwhile, 236 was tested a few times and MRK was rejected each time. With the last update on Keytruda, it's going to be interesting to see what comes next.
"Merck’s (NYSE:MRK) big news on July 27th marked a watershed moment for the company’s cancer treatment, Keytruda. The Food & Drug Administration approved Keytruda for treating patients with high-risk early-stage triple-negative breast cancer (TNBC), in combination with chemotherapy. Following surgery, Keytruda could then continue as a single agent adjuvant. This approval was based on Merck’s Phase 3 KEYNOTE-522 trial....Merck’s (NYSE: MRK) blockbuster drug, Keytruda, and Bristol-Myers’ YERVOY treatments target the same checkpoint inhibitors that are part of the B7 family (PD-1/PD-L1 and CTLA-4/CD80). They’ve also both demonstrated a clear survival benefit when it comes to immune-oncology treatment...This B7H3 protein is a checkpoint molecule, which has very recently become a target for cancer treatment."
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
SNY Fib Levels On The Radar & WhySNY and TBIO buttoned up the news this morning sending a bunch of other biotech stocks running higher. Now that this is out of the way, levels could be important for longs looking for "what's next" and the 236 Fib level seems to be that area to watch. It was an area that the volatile SNY stock settled above for weeks and now is an area it hasn't been able to break above for the last several weeks. Heading into the month after this acquisition, it's gonna be interesting to see if mRNA stocks start to catch a bit more.
" A mega buyout from Sanofi (NASDAQ: SNY) has investors looking at biotech stocks today. If you remember our article, “Top Biotech Penny Stocks On Robinhood To Watch This Week,” we discussed Sanofi and its strengthening relationship with a former penny stock, Translate Bio Inc. (NASDAQ: TBIO)...Sanofi had previously pledged to invest 400 million euros annually in a vaccines R&D facility to advance mRNA vaccines with Translate to benefit. Tuesday, Sanofi formally announced a $3.2 billion buyout of its vaccine collaboration partner. This was at $38 a share in cash, roughly 30% higher than the close on August 2nd. "
Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
Big Crash Incoming On BNTXThere will most likely be a 25% to 35% drop in BNTX over a very short period of time.
If we gap down Tuesday then expect it to drop the whole day.
Reasons: Price and volume divergence, over-extesnion of price and emotions, demand imbalances are way lower, topping formations intra-day.
Can GALT Vault Back Above The 200?Looks like GALT is back hanging out around the 786 level again. This is where it was trading around before the last big spike. But there's also another level to keep track of which is the 200DMA. Now that GALT is below this level, the 200 might be another possible area of resistance. Given the post-market action on Friday (7/30), GALT managed to break above the 200 ($2.82) briefly before sliding back down to that same level by the close of the aftermarket session.
Aside from technicals, there are also some fundamental things to note about GALT and you can Read More On GALT stock: 8 ‘Must Watch’ Penny Stocks For Your July 2021 List
DOUBLED $ATOS Target 5.69 for 46.27% DOUBLED $ATOS Target 5.69 for 46.27% (Actually I a little bit more than doubled here, but not by too much)
Next add level at 2.09
Or Double Position again at 1.48
@Dau30 Here is my new average after doubling this morning… and I have a small order open at 2.80 but I’m watching for 1.48. A WILD day, for sure...
-----
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
ONLY ADD at support levels & FIB levels… labeled
I start every position with .5 - 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed.
GL and happy trading.
NTEC Trying ....AGAINNTEC trying to break and hold above this 786 fib level ....AGAIN. It was a previous area of support leading up to the last sell-off but since breaking below it has remained a sticky level of resistance.
"Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from Decoy surfaced. It showed that this was for Decoy’s “Compositions and methods for treatment of cancer using bacteria’ and that the patent was granted. With the latest proposed merger seemingly coming to fruition, this additional piece could give the company more exposure to the mounting cancer trend in the market recently. Shares have catapulted to highs of $17.80 during the week."
Read More about this Decoy/Intec Deal: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
PAVM Wayback MachineHad to go way back to find some levels to plot against and 2017 looks like it's the mark. The interesting part is that this 236 area has been an area of traffic in the past. Considering that PAVM failed to break and hold (for now) once again might reinforce that idea. Prior to reaching those highs, the stock tested this area a few more times but failed at every pass besides 1.
"The progress from Lucid is one aspect that traders are watching with PAVmed. However, an earlier development this summer may have also acted as a catalyst for the record-setting move in 2021. Once again, this involves Lucid’s EsoGuard test. It received a European CE mark certification. This now allows the test to be marketed in numerous European countries...While PAVmed isn’t developing a cancer treatment, the EsoGuard platform is the first step to potential prevention. According to the company, it is the first and only commercially available diagnostic test capable of widespread screening to prevent esophageal cancer deaths through early detection of esophageal precancer and cancer in at-risk chronic heartburn patients."
Quote Source: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
FXCM's BioTech Basket Short-Term Pullback in Daily StrengthFXCM's BIOTECH basket is in the bullish area on the daily chart on the left. The basket is made up of equal weighting of 2% each in ABBV, AMGN, GILD, CELG and VRTX. A bullish cross of EMAs and stochastic potentially align short-term traders with the daily. If signals occur, movement of stochastic to 80 level and maintenance of that level increase chance of a successful trade in terms of 4 point pattern (red 1234). Trend following indicators may be useful in this case as a potential exit tool. Stop under hourly support in conjunction with risk management techniques.
Is LABD looking to break out of this ascending triangle?As far as popular reversal patterns go, ascending triangles are no bottom of the barrel. Although I still am a new trader, I have been committed to the market for just over 1 year. With that said I have been watching LABD/LABU in proximity of market trends. When the overall market is bullish I trade LABU with success. When Market is bearish I trade LABD with success. My number #1 rule is follow the trend. That is why I am bullish on LABD. With the market making irrational highs despite COVID fears of a new variant, I have noted that LABD make this ascending triangle formation. So far it has held true. This could just be paranoid shizophrenia (I have an MD by the way), but my inner voice has been telling me to watch biotech for the market fall. My theory is that if and when the market falls LABD is going to get pumped like there is no tomorrow, similar to the VIX. But the good part is it is not as volatile as fear is. I can trade its inverse and watch the volume in both directions. So far it seems even, so i don't think any one knows what is coming next, except for maybe the FED. Unless LABU turns around I think LABD can go up to 40, if in fact there is a bubble burst on the horizon.
The boomers didn't have enough kids trendThe london area and some countries are ordering millions of body bags.
They are super bearish. At the bottom. As usual.
Covid is over. There were 2 deadly waves and there won't be a third.
I hope I'm not offending anyone too much. I know that to big brains going against the fear narrative - which changes everyday - makes you a conspiracy theorist that believes jewish lizards control the world.
I believe reptilians control the world and this is my right.
Look at this chart:
Do you not think that governments are ran by reptilian brains because I think they are.
They made illegal buying masks and told us they were useless.
Then they forced us to wear masks and used strict police repression to enforce this rule.
They locked healthy people at home, even in middle ages they didn't do that.
Scientists proved it was useless AND showed that for the first time ever,
entire families (locked together) died!
They are always wrong about everything. They are reptilian peasants.
Covid passes, just like retirement reforms, are rules made by boomers for boomers.
And these rules apply to everyone except the police and military. Democracy.
It's like literally everyone is ultra bullish on covid but they are all wrong. This is the top.
They are going to panic with the violent 2023 flu pandemic but it's just the start of wave 1 in the new uptrend.
And 2022 will be "back to normal hurrah".
After 1 century of exceptional progress, S&P growth, life expectancy, the trend will reverse.
Good times create weak men etc. These weak zombies will panic it's going to be funny.
When a very violent bubonic ebola plague hits it's possible that the zombies get the zeal of the convert:
They believed in covid fear, they will change their mind once it's over and they slowly learn restrictions were for nothing. Redpilled.
And so, when the plague hits they will brush it off. I'll be in my bunker in the middle of nowhere watching natural selection take its course.
Deaths will actually go up for several reasons:
- Massive obesity, in particular in the young (that are getting older and fatter)
- Massive old population with very little replacement
And also:
- Weak chinned low T drug addicts
- Hypocondriacs with weakened immune systems
- Being stuck at home and other small reasons
Medical institutions have done a lot of campaigning to get people to avoid using antibiotics all the time.
Some fear penicillin resistant bacterias pandemics and mutants. This will not happen, not on a large scale.
Bacterias have been at war for BILLIONS of years. Using penicillin or other antibiotics for millions of years.
Zambia is a country with a population of 15,000,000.
The west stole almost all their doctors. They had 1600 and that number dropped to 400.
This obviously really screws the country beyond belief but a few thousand doctors for the west is not enough.
They have a few hundred per 100,000 and as the population age they will need more, perhaps as much as 500/100,000.
But their doctors are retiring, so the number goes down.
In France the number now is 330, stagnating, but the number of patients is going up.
And that 330 number will decline.
France alone might need 100 doctors by 100,000. So in total 67,000 doctors (the population is 67M).
That is more than 50 times the number of doctors that were stolen from Zambia.
And that's France alone.
Plus the "brain drain" has been going on for decades so Africa has little left to leech.
Maybe they are now letting in refugees because they hope some of them will turn into doctors?
For context at least 70% of refugees are women and children.
The revolution already started, but during the 2023 flu pandemic where thousands of old people are waiting in makeshift beds in tents because hospitals are full, and the government runs out of options (they might lock people at home again, out of despair again), a hard paradigm change will be necessary.
There are a lot of variable. For example if the anti covid injections have side effects, pharma companies, that already have scandals way too often, will lose the public trust. And the biotech period will not happen, or be delayed, or be very secondary. We are changing of paradigm & period (50-75 years), but also of era (200-300).
The period in France is 1968-2021 so 53 years. Or you could say since the 1946 NWO, 75 years. It is not an exact science.
The past 50-75 years was the period of neo-liberal pleasure seaking, tech religion, etc. It's ending.
That was for the period (50-75). The era (200-300) is industrial revolution/wageslavery/capitalism/socialism.
We were born just in time to witness some of the greatest change in history. Worth it.
All of Africa does not have enough doctors and nurses to take care of the hundred of millions of obese and old patients. Not even close.
The only half valid hope is technology but it won't magically save people.
Deaths will go up, like it or not.
And governments can crush revolts, but they can't crush the underlying fundamentals.
If Louis XVI had put an end to the tax revolt of 1789 (Like Macron put an end to the yellow vest tax revolt), monarchy would still have ended.
The trend, and what to expect is clear. I believe not 1 in a thousand knows this.
It is mathematically impossible the welfare state continues, government guarenteed pensions will vanish.
And it is mathematically impossible that our generation (Z to X) lives better than boomers.
For the first time the kids will not be better off than their parents.
Not only that but even much worse off.
I will add another call, gold, easy one:
I hate explaining the obvious but I have the intention to throw this at the face of dum dums.
Here I am so clear even a zombie should be able to understand:
Months ago me said covid-19 wave was over, and me said if other wave it would be other variant. Which was the case. That call aged well.
Now me say covid deaths any variant is over. I no care media say "ooga booga many case". Me say death spike covid any variant over. No more big spike.
No third deadly wave. Understand? Death. Not case. Regardless vaccines. All country same.
ADDED to $ATOS Target 6.84 for 35.71% 🟢 $ATOS Target 6.84 for 35.71%
This one was caught by support so I added… I’ll add again at support if it goes that way… And if it breaks below I’ll double at 3.24
-----
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
Numbers with an A are places that are a good idea to add if you can.
Numbers with a D are places where you should double your position.
I start every position with .5 - 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed.
GL and happy trading.
NURO Fibbing Right Now Or New Highs Next?I took the NURO chart out to 2019, which was the last time it traded around these levels. After plotting these fibs, wouldn't you know, the 236 and 382 lined up almost EXACTLY with today's action. The 382 could be an important level to watch as this was a prior area of "high traffic" and a support/resistance pivot in 2019. With volume surging, 382 fib line could be a key level t pay attention to.
**The big spike in trading action on July 20th stemmed from FDA news. NeuroMetrix announced that it received FDA Breakthrough Device Designation for treating fibromyalgia. Specifically, its Quell device garnered the interest of the stock market today. The device is non-invasive and is a nerve stimulator covered by 18 U.S. utility patents already. This Breakthrough Device Program aims to help patients gain quicker access to technologies like Quell that could provide more effective treatments.
“We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.”
Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix
Later this week, the company releases its Q2 results. So if NURO stock is on your list right now, keep July 22nd in mind. The company will also host a conference call before the market opens on that day. Read More On NeuroMetrix .**
Quote Source: 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
CEMI - **ON HIGH ALERT** - OTM OPTIONS $5 CALLS - WEEKLY / DAILYAll,
I think CEMI is due for a huge run here oversold massively on almost all timeframes like daily/weekly. This has been building up and end of pattern now. I'd either scale in or get OTM options but further out.
Between Two Fibs - AEMDAEMD seems to like this range between the 786 and 618 fib lines. The 618 has long-been a point of resistance on the chart. Meanwhile, the last few days have seen it test the 786 level but hold both above it AND its 50DMA. No news today but focus on biotechs thanks to CYTK earlier could be a sympathy trigger at play. Also with the Delta varient becoming "a thing," covid stocks in numerous stages of development are becoming more of a focus right now. We'll have to see if 786 fib+ 50DMA post a strong support level and if 618 will remain resistance if or when AEMD takes another swing at it.
Not Much Fib With NRXP But Levels, Yes!Fib Retracement on NRXP doesn't show much by way of "important levels" until you get to the 786 if you use that ATH for the top of your fib set-up. BUT if you look back on the chart, there's a pretty clear level right AT the area NRXP stock is trading at after this news. Around $12.70 was a previous area where the stock tested but didn't break below. Now, since breaking below, this seems to be a level that it can't break above. However, after the news came out, NRXP has treaded water between 11.50 & $12 in a consolidation trend during the 7/19 session. Volume will be something to keep an eye on moving forward in deciding which way it will break.
"Shares of NRXP were also going against the grain of the broader biotech trend at the start of the week. NRX Pharmaceuticals (NRXP Stock Report) announced that it will present data at the Disease Control and Prevention Summit this week. Wednesday (7/21) the company provides evidence that its YESAMI treatment might help prevent “cytokine storm” in patients with COVID-19.
According to the company, 'In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI™ had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the study.'”
Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
New Highs & Levels For CYTKCYTK put in a fresh high today which was rejected HARD almost immediately after. This came after the company announced positive topline results from 2 cohorts in its REDWOOD-HCM Phase 2 clinical trial of CK-3773274 (CK-274). This is the company’s investigational treatment targeting hypertrophic cardiomyopathy.
“The combined data from Cohorts 1 and 2 in REDWOOD-HCM met our high expectations for this trial of CK-274 in patients with obstructive HCM, given the observed onset of response to initiation of treatment, magnitude and breadth of response, reversibility of LVEF decreases, and favorable tolerability profile,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.
Looks like the 236 fib line - using lows from the major gap down - has been a pivot over the last year or so. CYTK tested that level on July 19th and bounced during the morning session. The big question is can it maintain this as a new support level or is it looking at another breakdown following this huge move?
"Thanks to these results, Cytokinetics expressed its anticipation of what its Phase 3 trial could bring to the table. Let’s put this into perspective. CYTK wasn’t any of the penny stocks that broke out last year. However, its valuation was a fraction of what it is today. Last October, CYTK stock was trading around $15 a share; more than 50% less than its value on July 19th. With that, attention is certainly on smaller biotech stocks right now."
Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech